JP2022523442A5 - - Google Patents

Info

Publication number
JP2022523442A5
JP2022523442A5 JP2021553382A JP2021553382A JP2022523442A5 JP 2022523442 A5 JP2022523442 A5 JP 2022523442A5 JP 2021553382 A JP2021553382 A JP 2021553382A JP 2021553382 A JP2021553382 A JP 2021553382A JP 2022523442 A5 JP2022523442 A5 JP 2022523442A5
Authority
JP
Japan
Application number
JP2021553382A
Other languages
Japanese (ja)
Other versions
JPWO2020183245A5 (https=
JP7566766B2 (ja
JP2022523442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000342 external-priority patent/WO2020183245A2/en
Publication of JP2022523442A publication Critical patent/JP2022523442A/ja
Publication of JPWO2020183245A5 publication Critical patent/JPWO2020183245A5/ja
Publication of JP2022523442A5 publication Critical patent/JP2022523442A5/ja
Priority to JP2024135000A priority Critical patent/JP2024170426A/ja
Application granted granted Critical
Publication of JP7566766B2 publication Critical patent/JP7566766B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021553382A 2019-03-11 2020-03-11 抗Vβ17/抗CD123二重特異性抗体 Active JP7566766B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135000A JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962816464P 2019-03-11 2019-03-11
US62/816,464 2019-03-11
PCT/IB2020/000342 WO2020183245A2 (en) 2019-03-11 2020-03-11 ANTI-Vβ17/ANTI-CD123 BISPECIFIC ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135000A Division JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Publications (4)

Publication Number Publication Date
JP2022523442A JP2022523442A (ja) 2022-04-22
JPWO2020183245A5 JPWO2020183245A5 (https=) 2023-03-17
JP2022523442A5 true JP2022523442A5 (https=) 2023-03-17
JP7566766B2 JP7566766B2 (ja) 2024-10-15

Family

ID=71670296

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021553382A Active JP7566766B2 (ja) 2019-03-11 2020-03-11 抗Vβ17/抗CD123二重特異性抗体
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135000A Pending JP2024170426A (ja) 2019-03-11 2024-08-13 抗Vβ17/抗CD123二重特異性抗体

Country Status (12)

Country Link
US (2) US12264197B2 (https=)
EP (1) EP3937977A2 (https=)
JP (2) JP7566766B2 (https=)
KR (1) KR20210138033A (https=)
CN (2) CN113874400B (https=)
AU (1) AU2020235475A1 (https=)
BR (1) BR112021017801A2 (https=)
CA (1) CA3132916A1 (https=)
IL (1) IL286147A (https=)
MA (1) MA55305A (https=)
MX (1) MX2021010857A (https=)
WO (1) WO2020183245A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス,インコーポレーテッド T細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
JP7566766B2 (ja) 2019-03-11 2024-10-15 ヤンセン バイオテツク,インコーポレーテツド 抗Vβ17/抗CD123二重特異性抗体
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4192481A4 (en) * 2020-08-10 2024-09-11 Janssen Biotech, Inc. MATERIALS AND METHODS FOR THE PRODUCTION OF VIRUS-SPECIFIC BIOMODIFIED LYMPHOCYTES
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
MX2023002948A (es) * 2020-09-11 2023-05-22 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadena beta.
KR20230084507A (ko) * 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도
TWI815194B (zh) * 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20250092134A1 (en) * 2021-11-01 2025-03-20 Janssen Biotech, Inc. Compositions and methods for the modulation of beta chain-mediated immunity
CA3251397A1 (en) * 2022-02-09 2023-08-17 Janssen Biotech, Inc. METHODS AND COMPOSITIONS COMPRISING COMPONENTS FOR BRINGING BISORPOSE VΒ17 T LYMPHOCYTES TO CONTACT WITH BIOMODIFIED VIRUS-SPECIFIC LYMPHOCYTES
WO2024166047A1 (en) * 2023-02-09 2024-08-15 Janssen Biotech, Inc. Anti-v beta 17/anti-cd123 bispecific antibodies

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6413516B1 (en) 1989-03-21 2002-07-02 The Immune Response Corporation Peptides and methods against psoriasis
FR2681875A1 (fr) 1991-09-26 1993-04-02 Immunotech Sa Nouvelles molecules de adn recombinants contenant la partie codante d'une chaine vb17 du recepteur pour l'antigene des cellules t, procede de preparation, anticorps et medicaments les renfermant.
US6084087A (en) 1991-09-27 2000-07-04 New York Society For The Ruptured And Crippled Maintaing The Hospital For Special Surgery DNA encoding conserved T-cell receptor sequences
PT1538206E (pt) 1997-09-16 2010-04-12 Centocor Ortho Biotech Inc Método para a síntese química e construção completa de genes e genomas
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
EP1789446A2 (en) 2004-09-02 2007-05-30 Genentech, Inc. Heteromultimeric molecules
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
US7585960B2 (en) 2005-05-11 2009-09-08 Theramab Gmbh Nucleic acids encoding superagonistic anti-CD28 antibodies
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20110097339A1 (en) 2008-07-18 2011-04-28 Domantis Limited Compositions monovalent for CD28 binding and methods of use
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6055404B2 (ja) 2010-06-15 2016-12-27 ゲンマブ エー/エス 組織因子に対するヒト抗体薬物結合体
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CA2854233C (en) 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
TWI485161B (zh) * 2012-03-02 2015-05-21 中央研究院 抗上皮細胞黏著分子(EpCAM)抗體及其使用方法
WO2014159531A1 (en) 2013-03-14 2014-10-02 The Board Of Regents Of The University Of Texas System Monoclonal antibodies targeting epcam for detection of prostate cancer lymph node metastases
CN113354744A (zh) 2013-12-20 2021-09-07 弗雷德哈钦森癌症研究中心 带标签的嵌合效应分子及其受体
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
JO3568B1 (ar) * 2014-09-05 2020-07-05 Janssen Pharmaceutica Nv عوامل ربط cd123 واستخداماتها
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
AR104250A1 (es) 2015-04-16 2017-07-05 Eisai R&D Man Co Ltd Anticuerpo anti-notch4 humano
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
CA2997444A1 (en) 2015-09-29 2017-04-06 Amgen Inc. Asgr inhibitors for reducing cholesterol levels
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
WO2018112407A1 (en) * 2016-12-15 2018-06-21 Duke University Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors
US11370830B2 (en) 2017-04-07 2022-06-28 The Rockefeller University Neutralizing antibodies that bind to the zika virus domain III envelope region
KR20200041834A (ko) 2017-06-01 2020-04-22 젠코어 인코포레이티드 Cd123 및 cd3에 결합하는 이중특이성 항체
CA3081539A1 (en) 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
GB2595980B (en) 2019-01-04 2023-06-14 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
JP7566766B2 (ja) 2019-03-11 2024-10-15 ヤンセン バイオテツク,インコーポレーテツド 抗Vβ17/抗CD123二重特異性抗体
AU2020298324A1 (en) 2019-06-21 2022-01-27 Single Cell Technology, Inc. Anti-TIGIT antibodies
US20210130440A1 (en) 2019-10-03 2021-05-06 Janssen Biotech, Inc. Methods for producing biotherapeutics with increased stability by sequence optimization
KR20220147631A (ko) 2020-02-27 2022-11-03 얀센 바이오테크 인코포레이티드 면역 반응을 조절하기 위한 물질 및 방법
MX2023002948A (es) 2020-09-11 2023-05-22 Janssen Biotech Inc Métodos y composiciones para modular la inmunidad mediada por cadena beta.
US12448449B2 (en) 2020-09-11 2025-10-21 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
KR20230084507A (ko) 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도

Similar Documents

Publication Publication Date Title
CN305554952S (https=)
CN305800686S (https=)
CN305536280S (https=)
CN305535459S (https=)
CN305813851S (https=)
CN305647066S (https=)
CN305534463S (https=)
CN305631112S (https=)
CN305534326S (https=)
CN305532726S (https=)
CN305530909S (https=)
CN305530131S (https=)
CN305528943S (https=)
CN305609507S (https=)
CN305528302S (https=)
CN305574520S (https=)
CN305528150S (https=)
CN305559938S (https=)
CN305558319S (https=)
CN305527079S (https=)
CN305527032S (https=)
CN305526779S (https=)
CN304981773S9 (https=)
CN305872737S (https=)
CN305556860S (https=)